Savior Lifetec Corp

Savior Lifetec Corp maintains a strong liquidity position, with a current ratio of 11.06, indicating a high ability to meet short-term obligations. The company holds TWD 588 million in cash and equivalents, while its total liabilities amount to TWD 404 million, resulting in a low debt-to-equity ratio of 0.05. This capital structure suggests a conservative approach to financing, with minimal reliance on long-term debt.

The company's profitability is robust, with a net income of TWD 537.45 million and a return on equity (ROE) of 14.22%, which is well above the industry median for pharmaceutical firms. Its return on assets (ROA) of 12.84% also reflects efficient asset utilization. These metrics suggest that the company is generating strong returns relative to its equity and asset base.

Geographically, Savior Lifetec Corp's revenue is concentrated in its domestic market, with no disclosed international segments. The company's business is primarily driven by its core pharmaceutical products, with no material diversification into other therapeutic areas or business lines. This concentration may expose the company to regulatory and market risks specific to its primary operating region.

Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. Historical revenue growth has been steady, and the company's free cash flow of TWD 356.52 million supports ongoing operations and potential reinvestment. However, the absence of disclosed capital expenditure plans beyond TWD 142.26 million suggests a cautious approach to expansion.

Risk factors for the company include the inherent volatility of the pharmaceutical industry, such as regulatory changes, patent expirations, and competitive pressures. The company's low dilution risk is supported by the absence of recent equity issuance or shelf registration activity. However, the low liquidity risk is partially offset by a negative operating cash flow of TWD 21.04 million, which may indicate inefficiencies in working capital management.

Recent events include the company's latest financial filing, which disclosed strong net income and a conservative capital structure. No material events, such as mergers, acquisitions, or significant legal proceedings, were reported in the most recent filings.